Lipolytic Effects of GH in Hypopituitary Patients in Vivo
Hypopituitarism, Insulin Resistance, Endocrine System Diseases
About this trial
This is an interventional basic science trial for Hypopituitarism
Eligibility Criteria
Inclusion Criteria:
- hypopituitary patients with documented GH-deficiency
Exclusion Criteria:
- other significant disease
Sites / Locations
- University Hospital of Aarhus
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Placebo Comparator
Placebo Comparator
Acipimox/GH substitution
Acipimox/GH pause
Placebo/GH substitution
Placebo/GH pause
Drug: Acipimox Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day Other Name: Tablet Olbetam 250 mg Continue GH substitution as usually.
Drug: Acipimox Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day Other Name: Tablet Olbetam 250 mg Pause GH substitution to days prior to the study day.
Drug: Placebo tablets Continue GH substitution as usually.
Drug: Placebo tablets Pause GH substitution to days prior to the study day.